我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
67
15 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2019
进行中（未招募）
14
20.9%
已完成
49
73.1%
尚未招募
1
1.5%
招募中
3
4.5%
暂无批准数据
- The World Health Organization has granted Phase II pre-qualification to Biological E Limited's Novel Oral Polio Vaccine type 2, enabling complete end-to-end manufacturing at a single integrated facility. - This milestone expands beyond the company's June 2024 Phase I qualification and allows for more resilient global vaccine supply for outbreak control efforts. - Biological E has already manufactured and supplied 700 million doses of nOPV2 to the global stockpile, with the vaccine deployed in over a billion doses worldwide. - The enhanced manufacturing capability strengthens global polio outbreak response readiness by providing continuous, flexible vaccine supply for controlling circulating vaccine-derived poliovirus type 2 outbreaks.
